Related Experiment Video
Updated: Aug 13, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Vascular protection from atherosclerosis: potential of calcium antagonists
1Division of Cardiology, University of California School of Medicine, San Francisco 94143.
Abstract:
Atherosclerosis is the result of complex, interrelated processes, many of which involve calcium. Interventions that interfere with calcium uptake by cells retard lesion development in experimental models of atherosclerosis, underscoring calcium's critical role in atherogenesis. A wide variety of calcium antagonists, including nifedipine, verapamil and diltiazem, have been shown to protect against atherosclerosis in animal models. While these drugs are quite different from each other pharmacologically, they all block intracellular calcium influx. This common property is thus the proposed mechanism for their antiatherosclerotic effects. The effectiveness of the calcium antagonists against the development of atherosclerosis in experimental models may be relevant in the selection of antihypertensive therapy--provided that their protective effects can be demonstrated in future clinical trials as well.
Insights
Calcium plays a key role in atherosclerosis development. Calcium channel blockers, like nifedipine, verapamil, and diltiazem, show promise in preventing atherosclerosis in animal models, suggesting potential benefits for hypertension therapy.
Area of Science:
- Cardiovascular Science
- Pharmacology
- Biomedical Research
Background:
- Atherosclerosis involves complex processes, with calcium playing a critical role.
- Calcium uptake by cells is implicated in lesion development.
- Existing research suggests calcium's central role in atherogenesis.
Purpose of the Study:
- To investigate the role of calcium in atherosclerosis.
- To evaluate the antiatherosclerotic effects of calcium antagonists in experimental models.
- To explore the potential of calcium antagonists in antihypertensive therapy.
Main Methods:
- Review of experimental models of atherosclerosis.
- Analysis of the effects of various calcium antagonists (nifedipine, verapamil, diltiazem).
- Focus on the mechanism of blocking intracellular calcium influx.
Main Results:
- Interventions inhibiting cellular calcium uptake retarded lesion development in experimental atherosclerosis.
- Calcium antagonists demonstrated protective effects against atherosclerosis in animal models.
- A common mechanism of action for these drugs is blocking intracellular calcium influx.
Conclusions:
- Calcium is critical in the pathogenesis of atherosclerosis.
- Calcium antagonists possess antiatherosclerotic properties in experimental settings.
- Further clinical trials are needed to confirm the relevance of these findings for human antihypertensive therapy selection.
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Vasodilators
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management

